Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early Alveolar Epithelial Cell Necrosis is a Potential Driver of ARDS with COVID-19

View ORCID ProfileKentaro Tojo, Natsuhiro Yamamoto, Nao Tamada, Takahiro Mihara, Miyo Abe, Mototsugu Nishii, Ichiro Takeuchi, Takahisa Goto
doi: https://doi.org/10.1101/2022.01.23.22269723
Kentaro Tojo
1Department of Anesthesiology and Critical Care Medicine, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kentaro Tojo
  • For correspondence: ktojo@yokohama-cu.ac.jp
Natsuhiro Yamamoto
1Department of Anesthesiology and Critical Care Medicine, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nao Tamada
1Department of Anesthesiology and Critical Care Medicine, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan
2Department of Paramedic, Kyorin University Faculty of Health Sciences, Mitaka, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takahiro Mihara
3Department of Health Data Science, Yokohama City University Graduate School of Data Science, Yokohama, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miyo Abe
1Department of Anesthesiology and Critical Care Medicine, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mototsugu Nishii
4Department of Emergency Medicine, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ichiro Takeuchi
4Department of Emergency Medicine, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takahisa Goto
1Department of Anesthesiology and Critical Care Medicine, Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Acute respiratory distress syndrome (ARDS) with COVID-19 is aggravated by hyperinflammatory responses even after the peak of viral load has passed; however, its underlying mechanisms remain unclear. Alveolar epithelial injury is reported to be a very early event in ARDS with COVID-19. Herein, we assessed whether necrosis of alveolar epithelial cells and subsequent releases of damage associated molecular patterns (DAMPs) at an early disease stage aggravates ARDS with COVID-19

Methods We analyzed the levels of cytokeratin18-M65, an epithelial total cell death marker; CK18-M30, an epithelial apoptosis-specific marker; and HMGB-1, one of the DAMPs released from necrotic cells, in patients with COVID-19 with and without ARDS and healthy adults, in addition to the circulating alveolar epithelial and endothelial injury markers, namely sRAGE, angiopoietin-2, and surfactant protein-D. Molecular mechanisms of alveolar epithelial cell death and effects of neutralization on alveolar tissue injury were assessed using a mouse model mimicking COVID-19-induced ARDS.

Results COVID-19-induced ARDS was characterized by the elevation of sRAGE, an epithelial injury marker, at a very early disease stage. Although both serum levels of CK18-M65 and CK18-M30 were elevated in COVID-19-induced ARDS, the median CK18-M30/M65 ratio, an indicator of the fraction of apoptosis among total epithelial cell death, was 31.5% in serum from COVID-19 patients with ARDS, a value significantly lower than that of non-ARDS patients or healthy subjects. Moreover, the median M30/M65 ratio in bronchoalveolar lavage fluid (BALF) in COVID-19-induced ARDS was 27.8%, indicating that alveolar epithelial cell death is mainly caused by necrosis. Serum levels of HMGB-1 were also significantly elevated in ARDS versus non-ARDS patients. In a mouse model mimicking COVID-19-induced ARDS, the ratio of CK18-M30 to a total epithelial cell death marker in BALF was also lower than that in control subjects. Moreover, the alveolar epithelial cell necrosis involved two forms of programmed necrosis: necroptosis and pyroptosis. Finally, neutralization of HMGB-1 attenuated alveolar tissue injury in the mouse model.

Conclusions Necrosis, including necroptosis and pyroptosis, seems to be the primary form of alveolar epithelial cell death and subsequent release of DAMPs is a potential driver of COVID-19-induced ARDS.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was partly supported by AMED under Grant Number JP20he0522001 and JSPS KAKENHI Grant Number 21K16575, and Grant for 2020-2021 Research Development Fund of Yokohama City University.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Yokohama City University Hospital institutional review board

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • We have added the analysis of bronchalveolar fluids of patients with COVID-19-induced ARDS.

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

  • List of abbreviations

    ARDS
    Acute respiratory distress syndrome
    ANG
    angiopoietin
    BALF
    bronchoalveolar lavage fluid
    COVID-19
    coronavirus disease 2019
    CK
    cytokeratin
    DAMPs
    damage-associated molecular patterns
    ELISA
    enzyme-linked immunosorbent assay
    HMGB
    high mobility group box
    LPS
    lipopolysaccharide
    PVDF
    polyvinylidene fluoride
    sRAGE
    receptors for advanced glycation end products
    SARS-CoV-2
    severe acute respiratory syndrome coronavirus 2
    SP
    surfactant protein
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
    Back to top
    PreviousNext
    Posted April 29, 2022.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Early Alveolar Epithelial Cell Necrosis is a Potential Driver of ARDS with COVID-19
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Early Alveolar Epithelial Cell Necrosis is a Potential Driver of ARDS with COVID-19
    Kentaro Tojo, Natsuhiro Yamamoto, Nao Tamada, Takahiro Mihara, Miyo Abe, Mototsugu Nishii, Ichiro Takeuchi, Takahisa Goto
    medRxiv 2022.01.23.22269723; doi: https://doi.org/10.1101/2022.01.23.22269723
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    Early Alveolar Epithelial Cell Necrosis is a Potential Driver of ARDS with COVID-19
    Kentaro Tojo, Natsuhiro Yamamoto, Nao Tamada, Takahiro Mihara, Miyo Abe, Mototsugu Nishii, Ichiro Takeuchi, Takahisa Goto
    medRxiv 2022.01.23.22269723; doi: https://doi.org/10.1101/2022.01.23.22269723

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Intensive Care and Critical Care Medicine
    Subject Areas
    All Articles
    • Addiction Medicine (162)
    • Allergy and Immunology (416)
    • Anesthesia (91)
    • Cardiovascular Medicine (863)
    • Dentistry and Oral Medicine (159)
    • Dermatology (98)
    • Emergency Medicine (251)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (394)
    • Epidemiology (8571)
    • Forensic Medicine (4)
    • Gastroenterology (388)
    • Genetic and Genomic Medicine (1759)
    • Geriatric Medicine (167)
    • Health Economics (373)
    • Health Informatics (1249)
    • Health Policy (622)
    • Health Systems and Quality Improvement (468)
    • Hematology (196)
    • HIV/AIDS (378)
    • Infectious Diseases (except HIV/AIDS) (10318)
    • Intensive Care and Critical Care Medicine (553)
    • Medical Education (192)
    • Medical Ethics (51)
    • Nephrology (213)
    • Neurology (1682)
    • Nursing (97)
    • Nutrition (252)
    • Obstetrics and Gynecology (328)
    • Occupational and Environmental Health (451)
    • Oncology (930)
    • Ophthalmology (264)
    • Orthopedics (102)
    • Otolaryngology (172)
    • Pain Medicine (114)
    • Palliative Medicine (40)
    • Pathology (253)
    • Pediatrics (538)
    • Pharmacology and Therapeutics (254)
    • Primary Care Research (209)
    • Psychiatry and Clinical Psychology (1775)
    • Public and Global Health (3853)
    • Radiology and Imaging (626)
    • Rehabilitation Medicine and Physical Therapy (320)
    • Respiratory Medicine (521)
    • Rheumatology (208)
    • Sexual and Reproductive Health (168)
    • Sports Medicine (158)
    • Surgery (191)
    • Toxicology (36)
    • Transplantation (101)
    • Urology (76)